Molecular genetics in myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1459-1462

  Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Cytogenetics; MDS; Molecular markers; Myelodysplastic syndromes; WHO classification

Indexed keywords

LENALIDOMIDE; MOLECULAR MARKER;

ASXL1 GENE; BLOOD SMEAR; BONE MARROW BIOPSY; CBL GENE; CELL STRUCTURE; CHROMOSOME BANDING PATTERN; CYTOPENIA; DISEASE CLASSIFICATION; DISEASE MARKER; ETV6 GENE; EXOME; EZH2 GENE; FLT3 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KRAS GENE; MLL PTD GENE; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; NRAS GENE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RUNX1 GENE; SF3B1 GENE; SRSF2 GENE; TET2 GENE; TP53 GENE; U2AF1 GENE; UTX GENE; WORLD HEALTH ORGANIZATION; WT1 GENE;

HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84868201807     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.009     Document Type: Review

References (26)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51(2):189-199.
2. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer (IARC), Lyon. 4th ed.
3. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
4. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood 2012, [Epub ahead of print].
5. Malcovati L., la Porta M.G., Pietra D., Boveri E., Pellagatti A., Galli A., et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009, 114(17):3538-3545.
6. Bacher U., Kern W., Alpermann T., Schnittger S., Haferlach C., Haferlach T. Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 2012, 36(7):826-831.
7. Haferlach T., Bacher U., Alpermann T., Haferlach C., Kern W., Schnittger S. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leuk Res 2012, 36(1):51-58.
8. Schanz J., Tuchler H., Sole F., Mallo M., Luno E., Cervera J., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012, 30(8):820-829.
9. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102(1):394-403.
10. Loken M.R., van de L.A., Ogata K., Orfao A., Wells D.A. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008, 32(1):5-17.
11. van de Loosdrecht A.A., Alhan C., Bene M.C., la Porta M.G., Drager A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94(8):1124-1134.
12. Kern W., Haferlach C., Schnittger S., Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010, 116(19):4549-4563.
13. Mills K.I., Kohlmann A., Williams P.M., Wieczorek L., Liu W.M., Li R., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114(5):1063-1072.
14. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004, 104(5):1474-1481.
15. Dicker F., Haferlach C., Sundermann J., Wendland N., Weiss T., Kern W., et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010, 24(8):1528-1532.
16. Jadersten M., Saft L., Smith A., Kulasekararaj A., Pomplun S., Gohring G., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011, 29(15):1971-1979.
17. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364(26):2496-2506.
18. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478(7367):64-69.
19. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365(15):1384-1395.
20. Patnaik M.M., Lasho T.L., Hodnefield J.M., Knudson R.A., Ketterling R.P., Garcia-Manero G., et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012, 119(2):569-572.
21. Kohlmann A., Grossmann V., Klein H.U., Schindela S., Weiss T., Kazak B., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010, 28(24):3858-3865.
22. Grossmann V., Kohlmann A., Zenger M., Schindela S., Eder C., Weissmann S., et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011, 25(3):557-560.
23. Meggendorfer M., Roller A., Haferlach T., Eder C., Dicker F., Grossmann V., Kohlmann A., Alpermann T., Yoshida K., Ogawa S., Koeffler H.P., Kern W., Haferlach C., Schnittger S. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012, [Epub ahead of print].
24. Kohlmann A., Grossmann V., Harbich S., Dicker F., Alpermann T., Nadarajah N., et al. Monitoring of minimal residual disease using next-generation deep-sequencing in 460 acute myeloid leukemia cases identifies RUNX1 mutated patients with resistant disease. Blood 2011, 118(21):747a.
25. Godley L.A. Profiles in leukemia. N Engl J Med 2012, 366(12):1152-1153.
26. Jeromin S., Haferlach T., Grossmann V., Alpermann T., Kowarsch A., Haferlach C., Kern W., Schnittger S. High frequencies of SF381 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2012, [Epub ahead of print].